Peregrine Capital Management LLC Makes New $5.71 Million Investment in NewAmsterdam Pharma Company N.V. $NAMS

Posted by Brian Himes on Jul 2nd, 2026

Peregrine Capital Management LLC purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 178,493 shares of the company’s stock, valued at approximately $5,714,000. Peregrine Capital Management LLC owned approximately 0.16% of NewAmsterdam Pharma as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC increased its stake in NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after buying an additional 708 shares during the period. Wells Fargo & Company MN boosted its position in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the period. Navalign LLC purchased a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $46,000. AdvisorNet Financial Inc acquired a new position in shares of NewAmsterdam Pharma in the first quarter worth $82,000. Finally, Empowered Funds LLC acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $85,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

NAMS has been the topic of a number of recent research reports. Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. Royal Bank Of Canada boosted their target price on NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

Check Out Our Latest Report on NAMS

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $869,158.57. This trade represents a 72.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Trading Up 3.8%

Shares of NAMS stock opened at $35.17 on Thursday. The firm has a fifty day moving average price of $32.82 and a 200 day moving average price of $33.10. The company has a market cap of $4.11 billion, a P/E ratio of -19.65 and a beta of 0.08. NewAmsterdam Pharma Company N.V. has a 12 month low of $18.08 and a 12 month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million during the quarter. On average, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current year.

NewAmsterdam Pharma Company Profile

(Free Report)

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.